# A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness

> **NCT03163511** · PHASE1,PHASE2 · COMPLETED · sponsor: **ViaCyte** · enrollment: 49 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus With Hypoglycemia

## Interventions

- **COMBINATION_PRODUCT:** VC-02 Combination Product

## Key facts

- **NCT ID:** NCT03163511
- **Lead sponsor:** ViaCyte
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-06
- **Primary completion:** 2023-10-13
- **Final completion:** 2023-10-19
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03163511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03163511, "A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03163511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*